Cost-effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States

OBJECTIVES: The phase 3 trial, RESPOND-2, demonstrated that the addition of boceprevir (BOC) to peginterferon-ribavirin (PR) resulted in significantly higher rates of sustained virologic response (SVR) in previously treated patients with chronic hepatitis C virus (HCV) genotype-1 infection as compar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chhatwal, Jagpreet, Ferrante, Shannon A., Brass, Cliff, El Khoury, Antoine C., Burroughs, Margaret, Bacon, Bruce, Esteban-Mur, Rafael, Elbasha, Elamin H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3820000/
https://ncbi.nlm.nih.gov/pubmed/24041347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jval.2013.07.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados